sertraline + lithium

Sertraline + lithium is a combination therapy consisting of two well-established pharmaceutical agents used primarily in the management of mood disorders, particularly bipolar disorder and treatment-resistant depression. Sertraline is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin levels by inhibiting its reuptake at the presynaptic neuron, thereby enhancing serotonergic neurotransmission. Lithium is a mood stabilizer with complex mechanisms, including modulation of neurotransmitter release and second messenger systems. The combination may be used when monotherapy with either agent is insufficient or in cases where augmentation strategies are required for resistant depression or bipolar II depression. Clinical studies indicate that this combination has similar efficacy and risk of mood switching compared to monotherapies but may have higher dropout rates due to tolerability issues[2][5][6]. Caution is warranted due to an increased risk for serotonin syndrome and other potential interactions[1][3][7][8].